Loading...
NPI 1174525604 · Edison, NJ · Specialist
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Mohammad Qureshi is a specialist provider located in Edison, New Jersey. This profile covers 40 Medicare and 11 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Mohammad Qureshi |
| Address | 300 Columbus Cir Ste A |
| City | Edison |
| State | NJ |
| ZIP | 08837 |
| Taxonomy | Specialist |
| NPI Enumerated | August 15, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $6.8M |
| Medicaid | $818.3K |
The provider's code mix is concentrated in high-volume diagnostic laboratory and pathology services rather than ambulatory clinical visits; dominant Medicare codes include molecular infectious-disease tests (87506, 87798, 87631, U0004/U0005) and a cluster of surgical pathology and immunohistochemistry codes (88305, 88313, 88342, 88344). This combination of NAAT-based infectious tests and multiple pathology IHC/stain codes indicates the operation functions as a high-throughput clinical laboratory with integrated anatomic pathology interpretation and specialized stool/GI assays.
Medicare revenue is highly concentrated: total Medicare revenue is $6.8M and the top three Medicare codes account for 64.5% of that Medicare revenue, with 87506 alone contributing $3.2M (48.4% of Medicare revenue). 87506 ranks #1 of 90 providers nationally (100th percentile; extreme outlier), signaling that this provider is an unusually large national biller for that specific GI multiplex nucleic acid test.
Medicaid revenue is dominated by COVID molecular testing: total Medicaid revenue is $818.3K and the top three Medicaid codes account for 98.7% of that Medicaid revenue, led by U0004 at $671.4K (82.1% of Medicaid revenue) and U0005 at $126.5K (15.5% of Medicaid revenue). Both codes are COVID PCR/high-throughput test lines, indicating the provider's Medicaid activity is largely driven by pandemic-era respiratory testing rather than broader pathology services.
Payer mix is Medicare-dominant: Medicare receipts ($6.8M) substantially exceed Medicaid receipts ($818.3K), indicating the provider relies primarily on Medicare volume for total billed revenue while maintaining a smaller, concentrated Medicaid footprint tied mostly to COVID testing. This profile reflects a lab operation where commercial/Medicare channels are the main revenue streams and Medicaid participation is focused on selected high-volume test lines.
The provider is a competitive outlier on several Medicare codes, suggesting national leadership in particular test lines: 88313 ranks #13 of 6757 providers (100th percentile; extreme outlier), 88342 ranks #25 of 11370 (100th percentile; extreme outlier), and 88305 ranks #109 of 14580 (99th percentile; extreme outlier). These percentile and rank positions imply the provider operates at volumes far above typical peers for multiple anatomic pathology and IHC services, consistent with a centralized reference lab or high-volume pathology practice.
By contrast, the provider's Medicaid competitive standing is modest within-state: U0004 ranks #24 of 67 providers in-state (65th percentile) and U0005 ranks #64 of 142 (55th percentile), which are in the middle of the state distribution and described as typical volumes. This indicates that while Medicaid billing is concentrated in a few COVID-related codes, the provider is not among the top state performers for those codes.
Several additional codes reinforce the lab-specialist posture through extreme-volume signals on niche assays: 82656 (pancreatic elastase) ranks #1 of 22 providers nationally (100th percentile; extreme outlier) and 82705 (fecal fat) ranks #1 of 95 providers nationally (100th percentile; extreme outlier), while 83993 (fecal calprotectin) ranks #2 of 166 (99th percentile; extreme outlier). High national ranks on these GI/stool assays point to a service line specialization in gastrointestinal diagnostic testing alongside core pathology/IHC services.
The provider has long-tenure billing presence with an NPI enumerated 2005-08-15 (~21 years ago), and the combination of sustained enrollment plus repeated extreme-outlier ranks on multiple lab and pathology codes suggests an established, high-throughput laboratory or pathology operation rather than a recent or low-volume starter. This longevity supports the interpretation that the current code mix and volumes reflect an operational strategy focused on centralized diagnostic testing over many years.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
40 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87506 | The lab analyst performs a test to detect six to eleven types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that cause gastrointestinal… | 12,550 | $260 | $3.2M |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 16,520 | $30 | $545.3K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 15,590 | $30 | $530.1K |
| 88313 | The lab analyst performs the technical lab steps to stain a specimen for Group II identification, for example an iron stain or trichrome stain. A qualified provider, typically a pathologist,… | 6,800 | $70 | $448.8K |
| 88342 | The lab analyst applies an initial single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist,… | 5,240 | $60 | $330K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 1,600 | $140 | $223.3K |
| 88120 | The lab analyst performs a technical lab test on a urinary tract specimen using in situ hybridization and three to five molecular probes for manual morphometric analysis, looking at the number and… | 380 | $520 | $195.4K |
| 83993 | The lab analyst performs the technical lab test on a small amount of stool sample to measure the amount of calprotectin, typically using an enzyme linked immunosorbent assay, or ELISA, test… | 9,830 | $20 | $186.8K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 1,690 | $70 | $124.8K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 1,430 | $70 | $98.5K |
Showing 1–10 of 40
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 40 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
40 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87506 | 1 | 10 | 110 | $260 | $506.1K |
| 87798 | 6 | 40 | 1,760 | $30 | $284.3K |
| 88120 | 6 | 20 | 200 | $350 | $278K |
| U0004 | 6 | 20 | 360 | $70 | $116.2K |
| 87591 | 13 | 10 | 140 | $30 | $73K |
| 88305 | 3 | 290 | 720 | $40 | $71.8K |
| 87801 | 3 | 20 | 300 | $70 | $70.5K |
| 87491 | 14 | 20 | 130 | $30 | $68.6K |
| 87481 | 6 | 50 | 100 | $30 | $60.3K |
| 83520 | 5 | 20 | 240 | $20 | $50.6K |
Showing 1–10 of 40
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
11 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 10,490 | $60 | $671.4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 7,030 | $20 | $126.5K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 870 | $10 | $9.6K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 50 | $70 | $3.3K |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 50 | $50 | $2.6K |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 160 | $20 | $2.6K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 100 | $10 | $800 |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 20 | $20 | $340 |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 20 | $20 | $340 |
| 88312 | The lab analyst performs the technical lab steps to stain a specimen with a special stain. This code applies to Group I for microorganisms. A qualified provider, typically a pathologist, interprets… | 20 | $1 | $100 |
Showing 1–10 of 11
How this provider's Medicaid billing volume and revenue compare to other New Jersey providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New Jersey median
11 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 24 | 70 | 4,800 | $50 | $1M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 64 | 140 | 5,590 | $20 | $823.1K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 86 | 90 | 630 | $30 | $806.2K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 174 | 210 | 1,660 | $60 | $347.9K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 50 | 60 | 720 | $40 | $249.7K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 65 | 180 | 320 | $10 | $116.9K |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 15 | 20 | 130 | $100 | $105K |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 49 | 60 | 940 | $10 | $44.4K |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 63 | 60 | 940 | $10 | $43.1K |
| 88312 | The lab analyst performs the technical lab steps to stain a specimen with a special stain. This code applies to Group I for microorganisms. A qualified provider, typically a pathologist, interprets… | 93 | 100 | 370 | $30 | $34.4K |
Showing 1–10 of 11
Other providers in the same ZIP code as Mohammad Qureshi, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.